The stock has a 36-month beta value of 2.19. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MGNX is 58.52M, and at present, short sellers hold a 14.69% of that float. On May 08, 2024, the average trading volume of MGNX was 1.43M shares.
MGNX) stock’s latest price update
The stock of Macrogenics Inc (NASDAQ: MGNX) has decreased by -8.94 when compared to last closing price of 16.05. Despite this, the company has experienced a -6.01% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-05-03 that ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET.
MGNX’s Market Performance
MGNX’s stock has fallen by -6.01% in the past week, with a monthly drop of -19.25% and a quarterly drop of -16.15%. The volatility ratio for the week is 6.60% while the volatility levels for the last 30 days are 6.34% for Macrogenics Inc The simple moving average for the past 20 days is -8.78% for MGNX’s stock, with a 43.68% simple moving average for the past 200 days.
Analysts’ Opinion of MGNX
Many brokerage firms have already submitted their reports for MGNX stocks, with B. Riley Securities repeating the rating for MGNX by listing it as a “Buy.” The predicted price for MGNX in the upcoming period, according to B. Riley Securities is $25 based on the research report published on April 26, 2024 of the current year 2024.
BTIG Research gave a rating of “Buy” to MGNX, setting the target price at $24 in the report published on March 04th of the current year.
MGNX Trading at -11.31% from the 50-Day Moving Average
After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.20% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 6.60%, as shares sank -20.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.87% lower at present.
During the last 5 trading sessions, MGNX fell by -6.62%, which changed the moving average for the period of 200-days by +200.62% in comparison to the 20-day moving average, which settled at $15.84. In addition, Macrogenics Inc saw 51.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGNX starting from Peters Jeffrey Stuart, who sale 51,395 shares at the price of $15.55 back on Apr 04 ’24. After this action, Peters Jeffrey Stuart now owns 0 shares of Macrogenics Inc, valued at $799,148 using the latest closing price.
Peters Jeffrey Stuart, the Senior VP and General Counsel of Macrogenics Inc, sale 19,625 shares at $21.50 during a trade that took place back on Mar 06 ’24, which means that Peters Jeffrey Stuart is holding 8,895 shares at $421,938 based on the most recent closing price.
Stock Fundamentals for MGNX
Current profitability levels for the company are sitting at:
- -2.86 for the present operating margin
- 0.99 for the gross margin
The net margin for Macrogenics Inc stands at -0.15. The total capital return value is set at -0.69. Equity return is now at value -6.15, with -3.04 for asset returns.
Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.3. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 117.65.
Currently, EBITDA for the company is -168.24 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 14.16. The receivables turnover for the company is 5.67for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
To sum up, Macrogenics Inc (MGNX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
